---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-24-000192"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:47:22.631607+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Humacyte ATEV meets Phase 3 co-primary endpoints; superior to AV fistula in hemodialysis

## Summary
- ATEV showed functional patency 81.3% at 6 months vs 66.4% for AV fistula; secondary patency 68.3% vs 62.2% at 12 months (joint p=0.0071).
- Subgroup analyses: ATEV superior in female (p<0.0001), obese (p=0.0001), and diabetic (p=0.0024) patients for patency rates and hemodialysis duration.
- Thrombosis reported in 52.1% of ATEV patients vs 9.1% for AV fistula; 94% of thrombotic events successfully treated.
- Infection rates low and similar: 9.1% ATEV vs 9.9% AV fistula.
- Phase 3 trial enrolled 242 hemodialysis patients in US; ATEV is investigational and not yet FDA-approved.

## SEC filing metadata
- accession: 0001818382-24-000192
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000192/0001818382-24-000192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000192/huma-20241028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-24-000192
- JSON: https://secwatch.observer/filing/0001818382-24-000192.json
- Plain text: https://secwatch.observer/filing/0001818382-24-000192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.